Does adding bupropion (Bupropion) correct hyperprolactinemia induced by Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)?

Bupropion for SNRI-Induced Hyperprolactinemia

Bupropion is likely effective in correcting hyperprolactinemia induced by Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) due to its dopaminergic mechanism of action, which counteracts the serotonergic effects that cause prolactin elevation. 1

Mechanism of Action and Rationale

Hyperprolactinemia from SNRIs occurs through the following mechanism:

• SNRIs increase serotonin levels, which stimulate 5-HT receptors
• This activation inhibits dopamine release in the tuberoinfundibular pathway
• Reduced dopamine leads to increased prolactin secretion from the pituitary 2

Bupropion works to correct this by:

• Acting as a dopamine-norepinephrine reuptake inhibitor 3
• Increasing dopamine levels in the tuberoinfundibular pathway
• Restoring the inhibitory effect of dopamine on prolactin secretion

Evidence Supporting Bupropion Use

Bupropion has several characteristics that make it suitable for treating SNRI-induced hyperprolactinemia:

1. Unique Pharmacological Profile: Bupropion is devoid of serotonergic effects, unlike other antidepressants that can cause hyperprolactinemia 3

2. Dopaminergic Action: As a dopamine reuptake inhibitor, bupropion increases dopamine levels, which naturally suppresses prolactin secretion 3

3. Established Use in Combination Therapy: Bupropion is frequently used in combination with SSRIs and SNRIs to address side effects while maintaining antidepressant efficacy 4

Clinical Approach to SNRI-Induced Hyperprolactinemia

First-Line Management:

1. Confirm the diagnosis:

   • Measure serum prolactin levels
   • Rule out other causes of hyperprolactinemia (pregnancy, hypothyroidism, pituitary adenoma) 5
   • Establish temporal relationship between SNRI initiation and hyperprolactinemia

2. Consider bupropion addition:

   • Starting dose: 150 mg once daily for 3 days
   • Increase to 150 mg twice daily if tolerated
   • Maximum daily dose: 300 mg to minimize seizure risk 1

3. Monitor response:

   • Check prolactin levels 4-6 weeks after starting bupropion
   • Assess for improvement in hyperprolactinemia-related symptoms

Alternative Approaches:

1. Dopamine agonists: If bupropion is ineffective or contraindicated, consider cabergoline as it is the dopamine agonist of choice for treating hyperprolactinemia 5, 6

2. SNRI dose reduction: Consider lowering the SNRI dose if clinically appropriate

3. SNRI switch: Consider switching to SNRIs less associated with hyperprolactinemia (duloxetine, milnacipran) 2

Precautions and Monitoring

When using bupropion to treat SNRI-induced hyperprolactinemia:

• Seizure risk: Monitor patients with risk factors for seizures 1
• Drug interactions: Evaluate potential interactions between bupropion and the SNRI 1
• Common side effects: Watch for insomnia, dry mouth, headache, and nausea 1
• Contraindications: Avoid in patients with seizure disorders or concurrent MAO inhibitor use 1

Special Considerations

• In cases where medication-induced hyperprolactinemia cannot be corrected and the causative medication cannot be withdrawn, it is important to verify the absence of pituitary adenoma 6

• For patients with macroprolactinoma, dopamine agonists like cabergoline are the first-line treatment rather than bupropion 5

• Regular monitoring of prolactin levels is essential to assess treatment response and detect any recurrence of hyperprolactinemia 6

By addressing the underlying dopaminergic deficit caused by SNRIs, bupropion represents a rational pharmacological approach to correcting SNRI-induced hyperprolactinemia while potentially enhancing the antidepressant effect.